Health ❯ Healthcare ❯ Pharmaceuticals

Medications

GLP-1 Drugs Weight Loss GLP-1 Receptor Agonists Semaglutide Weight Loss Drugs Tirzepatide Wegovy Alzheimer's Disease GLP-1 Agonists Weight Loss Treatments

Canada Expands Access to Semaglutide With Home Delivery and First G7 Generics

U.S. patients face years-long waits for approved generics due to extended Novo Nordisk patents.

Angelini Pharma to Acquire Catalyst Pharmaceuticals for $4.1 Billion in Cash

FDA Approves Auvelity as First Non‑Antipsychotic for Alzheimer’s Agitation

Lilly Shares Slip as Foundayo’s Second-Week Prescriptions Trail Wegovy

Anvisa Recalls Hypofarma Dipyrone Lot and Suspends All Mali Produtos Para Saúde Lots Over Quality Breaches

Mexico Renews Warning as Counterfeit GLP-1 Weight-Loss Drugs Spread Worldwide

Germany to Cover Four Off-Label Drugs for Long Covid Under Statutory Insurance

Semaglutide Patent Expires in Brazil, Opening Door to Lower-Cost Rivals

Anvisa Authorizes Multidose Mounjaro Pen for Brazil

Brazil's Semaglutide Patent Expires Friday, Opening Door to Ozempic Generics

New Study Finds Nearly Fivefold Higher Reported ‘Eye Stroke’ Risk With Wegovy vs Ozempic

France’s First In-Utero Treatment Shrinks Fetal Vascular Tumor, Baby Avoids Intubation

Democratic Report Puts TrumpRx Under Fresh Scrutiny as Analyses Question Real-World Savings

Brazil Government Opposes Patent Breaks for Weight-Loss Pens After House Fast-Tracks Bill

Major Lancet Analysis Finds Most Statin Label Side Effects Not Caused by the Drugs

Major Lancet Meta-Analysis Finds Statins Don’t Cause Most Listed Side Effects

Anvisa Expands Wegovy and Ozempic Uses to Cardiovascular and Kidney Protection

UK Regulator Flags Rare Pancreatitis, Including Deaths, Tied to Wegovy and Mounjaro

Russia Approves Adult Influenza Care Standard and Publishes Official Drug List

Wegovy Pill Posts Strong U.S. Debut as U.K. Authorizes Higher 7.2 mg Injectable Dose